Kyle A. Harris’ practice focuses on public and private mergers and acquisitions and corporate governance matters.

His experience spans the range of M&A activity, including both domestic and cross-border mergers, acquisitions, leveraged buyouts, carve-outs, divestitures, joint ventures, and other complex corporate transactions, as well as shareholder activism and takeover defense. He also regularly advises companies and their boards on fiduciary duties, corporate governance, and securities law matters.

He has significant experience representing public and private companies and investors in transactions across a broad array of industries, including chemicals and industrials, health care and pharmaceuticals, and TMT.

Kyle was named a “Rising Star” in M&A by Law360 in 2020, recognizing him as one of five outstanding M&A lawyers in the U.S. under the age of 40 “whose legal accomplishments transcend their age.” He was also named a 2020 “Rising Star” by The Deal in The Dealmaker Quarterly and a “Rising Star” by Expert Guides in 2021 and 2022.

Kyle frequently writes and speaks about M&A, securities laws, corporate governance, and other legal issues. His writings have been featured in the Harvard Law School Forum on Corporate Governance and Financial Regulation and The Columbia Law School Blue Sky Blog.

Kyle is also active in the firm’s pro bono practice. Among other matters, he serves as regular outside counsel to the Envision Freedom Fund (formerly the Brooklyn Community Bail Fund). He is a member of the New York State Attorney General’s Pro Bono Task Force for Reproductive Health.

Kyle joined the firm in 2011 and became a partner in 2020.

Notable Experiences

  • WPP in its acquisition of Fenom Digital.

  • Compass Minerals in its $252 million strategic equity investment partnership with KM&T.

  • International Flavors & Fragrances in its $1.3 billion sale of its Microbial Control business unit to Lanxess, $45.4 billion Reverse Morris Trust merger with DuPont’s Nutrition & Biosciences business, and $7.1 billion acquisition of Frutarom.

  • Finsbury Glover Hering in its merger with Sard Verbinnen & Co., and previously represented Finsbury in the formation of Finsbury Glover Hering.

  • AdvanSix in its acquisition of U.S. Amines.

  • dMY Technology Group III in its merger with IonQ to become the first publicly traded pure-play quantum computing company.

  • Astound Broadband in its $8.1 billion sale to Stonepeak Infrastructure Partners.

  • América Móvil in its $6.25 billion sale of TracFone Wireless to Verizon Communications and $905 million acquisition of Nextel Brazil.

  • Ness in its acquisition of Risk Focus.

  • Warburg Pincus in numerous transactions, including:

    • its investment, along with Berkshire Partners, in Ensemble Health Partners.
    • its acquisitions of Certified Labs, CityMD, Guardsmark, Food Safety Net Services, and Universal Services of America.
    • the merger of equals of Universal Services of America and AlliedBarton Security Services, creating Allied Universal.
  • Allied Universal in numerous matters, including its sale of a significant equity stake to CDPQ and investment funds affiliated with Warburg Pincus at a valuation of more than $7 billion, and in its acquisition of SOS Security.

  • MEDNAX in its sale of American Anesthesiology and in its defense against an activism campaign led by Starboard.

  • Bemis in its $6.8 billion all-stock combination with Amcor.

  • Dun & Bradstreet in its $6.9 billion all-cash sale of the company to a private equity consortium.

  • Kindred Healthcare in its $4.1 billion sale to a consortium led by TPG, Welsh Carson Anderson & Stowe, and Humana.

  • TPG Capital in its $2.25 billion acquisition of RCN and Grande Communications.

  • RCN in its $2.36 billion acquisition of Wave Broadband.

  • Google in its $1.1 billion agreement with HTC relating to the smartphone design business.

  • The Raine Group in its investments in Imagine Entertainment and Important Studios.

  • Kroll Bond Rating Agency in its sale to Wharf Street LLC.

  • Allergan in its $160 billion announced merger with Pfizer.

  • Silver Point Capital in its sale of Affinity Gaming.

  • Kindred Healthcare in its unsolicited tender offer to acquire Gentiva Health Services and the resulting $1.8 billion negotiated acquisition.

  • GlaxoSmithKline in its unsolicited tender offer to acquire Human Genome Sciences and the resulting $3.6 billion negotiated acquisition.

  • Lafarge in the divestiture of its cement operations in Ecuador and in various divestitures in connection with its €40 billion merger of equals with Holcim.

  • Pluspetrol Resources in its announced acquisition of substantially all of the assets of Harvest Natural Resources.

See More

Selected Activities

  • Senior Editor, The Journal of Constitutional Law, University of Pennsylvania Law School